ArticleJournal of medicinal chemistry2006
Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure.
Article in Journal of medicinal chemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Drug Development against Smallpox: Present and Future.Antimicrobial agents and chemotherapy · 2020Review
- Multicomponent reactions in nucleoside chemistry.Beilstein journal of organic chemistry · 2014Review
- KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo.Antimicrobial agents and chemotherapy · 2014Article
- Orthopoxvirus targets for the development of new antiviral agents.Antiviral research · 2012Review
- Article
- Ionic liquid-promoted multi-component reaction: novel and efficient preparation of pyrazolo[3,4-b]pyridinone, pyrazolo[3,4-b]-quinolinone and their hybrids with pyrimidine nucleoside.Molecular diversity · 2010Article
- Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.Antimicrobial agents and chemotherapy · 2009Article
- Ionic liquid promoted preparation of 4H-thiopyran and pyrimidine nucleoside-thiopyran hybrids through one-pot multi-component reaction of thioamide.Molecular diversity · 2009Article
- Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues.Bioorganic chemistry · 2007Article
- Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.Antimicrobial agents and chemotherapy · 2007Article
- Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.BMC structural biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Two privileged drug scaffolds have been hybridized to create the novel heteromorphic nucleoside 5-(2-amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-yl)-1-(2-deoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione (2). Compound 2 inhibited the replication of two orthopoxviruses, vaccinia virus (VV) (EC(50) = 4.6 +/- 2.0 microM), and cowpox virus (CV) (EC(50) = 2.0 +/- 0.3 microM). Compound 2 exhibited reduced activity against a thymidine kinase (TK) negative strain of CV, implying a requirement for 5'-monophosphorylation for antiorthopoxvirus activity. Compound 2 was efficiently phosphorylated by VV TK, establishing that VV TK is more promiscuous than previously believed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.